| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | J&J raises FY26 outlook following positive Q2 | ||
| Mi | Women's health attracted record equity in 2025 as companies share capital | ||
| Mi | AAIC26: The role of biomarkers in primary care and early diagnostics | ||
| Mi | FDA grants priority review to Roche's Gazyva/Gazyvaro for pMN | ||
| Mi | Innovent licenses IBI355 rights to Spero for up to $1.1bn | ||
| Di | AstraZeneca pays up to $1.5bn to license Dizal Pharma's lung cancer drug | ||
| Di | Novartis and Chai Discovery collaborate on antibody identification | ||
| Di | Cellares and Sonoma partner to automate cell therapy manufacturing | ||
| Mo | Germany approves healthcare costs overhaul despite significant pharma opposition | ||
| Mo | "Hub-and-spoke" drug manufacturing set to benefit from new FDA rule | ||
| Mo | Takeda and Indonesia partner on plasma-derived therapies | ||
| Mo | FDA approves MSD's Keytruda combinations for MIBC | ||
| Fr | Bayer banks €3bn in Apollo contraceptives division deal | ||
| Fr | Chinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RA | ||
| Fr | Ipsen set to rival Botox after duo of Phase III migraine wins | ||
| Fr | Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar | ||
| Fr | Apertura and NIH institutes to test gene therapy for NPC1 | ||
| 09.07. | Moderna secures up to 24 million RSV vaccine dose contract with Europe | ||
| 09.07. | Sino and AstraZeneca sign licence agreement for TQC3721 | ||
| 09.07. | Evogene and Tel Aviv University launch drug discovery initiative | ||
| 08.07. | FDA cracks down on illegal ketamine sellers amid nearing 'psychedelic revolution' | ||
| 08.07. | Kalohexis confidentially files IPO to back obesity and cachexia portfolio | ||
| 08.07. | Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant | ||
| 08.07. | FDA grants rare paediatric designation to Vanda's CMT2S therapy | ||
| 08.07. | Biocytogen and Whitehawk partner to develop ADCs |